InvestorsHub Logo
Followers 129
Posts 23648
Boards Moderated 1
Alias Born 09/14/2016

Re: None

Monday, 10/15/2018 9:52:03 AM

Monday, October 15, 2018 9:52:03 AM

Post# of 118363
$RGBP reports its researchers have determined that its lead NR2F6 small molecule agonist, RG-NAH005, is now ready for testing in animal models of inflammatory bowel disease (IBD). The Company will pursue this testing as a joint venture with Zander Therapeutics Inc. Zander Therapeutics, Inc. has been granted an exclusive license by Regen to develop and commercialize Regen's NR2F6 intellectual property for veterinary applications.

https://finance.yahoo.com/news/regen-biopharma-inc-determines-lead-200000491.html